Literature DB >> 3943054

Nonrandom chromosome structural aberrations and oncogene loci in human malignant melanoma.

M I Pedersen, J W Bennett, N Wang.   

Abstract

Short-term cultures of 10 malignant melanomas derived from 8 patients were analyzed cytogenetically. The chromosome composition of the tumors was found to be similar in terms of modal number and structural and numerical aberrations, especially the nonrandom nature of breakpoints. Six chromosomes were consistently involved in marker formation. Aberrations of chromosomes #1 and #9 were identified in every tumor, whereas structural alterations of chromosome #2 were found in 9 tumors. In contrast, aberrations of chromosomes #6, #3, and #7 were identified in 7, 7, and 8 of the tumors, respectively. The nonrandom breakpoints on these chromosomes frequently coincided with known oncogenic loci and resulted in morphologically identical marker chromosomes. Consecutive lesions were obtained for two patients. Common markers were identified in both cases, indicating the clonal origin of the tumors. In addition, many marker chromosomes characteristic of the individual lesions were also identified. The presence of these lesion-specific markers indicates the nonrandom selective nature of the metastatic process and suggests the possible heterogeneity of the original tumor cell population.

Entities:  

Mesh:

Year:  1986        PMID: 3943054     DOI: 10.1016/0165-4608(86)90103-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  12 in total

1.  Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines.

Authors:  A J Linnenbach; K Huebner; E P Reddy; M Herlyn; A H Parmiter; P C Nowell; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

2.  Chromosome abnormalities in metastatic melanoma.

Authors:  S Rauth; A Green; L Bratescu; T K Das Gupta
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-02       Impact factor: 2.416

3.  Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers.

Authors:  M A Herrmann; I D Hay; D H Bartelt; S R Ritland; R J Dahl; C S Grant; R B Jenkins
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

4.  Confirmation of chromosome 9p linkage in familial melanoma.

Authors:  D J Nancarrow; G J Mann; E A Holland; G J Walker; S C Beaton; M K Walters; C Luxford; J M Palmer; J A Donald; J L Weber
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

Review 5.  Cytogenetics of human malignant melanoma.

Authors:  J M Trent
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

6.  High incidence of chromosomal lesions involving C-heterochromatin in four human melanoma lines.

Authors:  L Larizza; L Doneda; M Rodolfo; G Fossati
Journal:  Clin Exp Metastasis       Date:  1989 Nov-Dec       Impact factor: 5.150

7.  Pigmented esthesioneuroblastoma showing dual differentiation following transplantation in nude mice. An immunohistochemical, electron microscopical, and cytogenetic analysis.

Authors:  A Llombart-Bosch; C Carda; A Peydro-Olaya; R Noguera; J Boix; A Pellin
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

8.  Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts).

Authors:  S M Langezaal; J F Graadt van Roggen; A M Cleton-Jansen; J J Baelde; P C Hogendoorn
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

9.  Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.

Authors:  G M Kraehn; J Utikal; M Udart; K M Greulich; G Bezold; P Kaskel; U Leiter; R U Peter
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

10.  Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation.

Authors:  A N Houghton; A P Albino; C Cordon-Cardo; L J Davis; M Eisinger
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.